Life sciences and diagnostics firm Revvity (RVTY) closed 2025 with results surpassing internal targets, driven by robust diagnostics performance. While management provided initial 2026 guidance, it remains conservative, banking on market stabilization rather than a broad recovery.
Life sciences firm Revvity (NYSE:RVTY) reported fourth-quarter revenue and profit that topped Wall Street forecasts, though analysts remain watchful of the company's ability to sustain momentum beyond recent quarters.
In a strategic reversal, GSK has handed back global rights to the clinical-stage RNA editing drug WVE-006 to Wave Life Sciences. Wave asserts the move allows it to faster advance the potential 'functional cure' for alpha-1 antitrypsin deficiency, while GSK refocuses on broader respiratory markets.
Harmony Biosciences CFO Sandip Kapadia has liquidated his entire direct stake in the company, a move that contrasts sharply with the firm's robust financial performance and bullish $1 billion revenue target for its flagship drug WAKIX by 2026. While the sales were pre-planned, the timing fuels debate on insider confidence versus corporate optimism.
Guggenheim analyst Subbu Nambi raises her price target on Bruker Corporation (BRKR) from $53 to $58, maintaining a Buy rating and projecting nearly 25% upside, as the life sciences tools sector shows resilience.
As the Bank of Canada signals a hold on interest rates, a backdrop of market stability is emerging. This analysis delves into three Canadian penny stocks—Britannia Life Sciences, ROK Resources, and Vision Lithium—that present distinct risk-reward profiles for investors eyeing the junior markets in early 2026.
Shares of life sciences toolmaker Qiagen (NYSE:QGEN) have shown renewed momentum, gaining over 12% in the past month. This surge brings the company's valuation into sharp focus, with analysts divided between near-term earnings multiples and long-term cash flow projections.
Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.
Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.
Becton Dickinson announces a major spin-off of its Biosciences unit to combine with Waters Corporation, alongside a successful pilot to recycle polystyrene labware, signaling a dual push towards portfolio focus and sustainability.
Veeva Systems' stock has faced recent pressure, declining over 11% in the past year. A deep dive into its valuation reveals a stark contrast: a discounted cash flow model suggests significant upside, while its premium P/E ratio tells a more cautious tale. We examine the numbers and what they mean for investors eyeing the life sciences cloud leader.
After Abbott Laboratories' stock plunged nearly 10% on disappointing revenue, CEO Robert B. Ford made a significant personal investment, purchasing $2 million in company shares. This move, seen as a strong signal of insider confidence, highlights a clash between short-term market jitters and long-term corporate strategy.
Amid a challenging market for biotech, C4 Therapeutics (NASDAQ: CCCC) is drawing investor attention with its targeted protein degradation platform. Backed by industry giants and focused on niche cancers, the clinical-stage company presents a high-risk, high-reward proposition. We examine the bull case and the road ahead.
After a period of significant volatility, Neogen Corporation (NEOG) is showing signs of a sustainable operational turnaround under new leadership, with its latest quarterly results beating expectations and prompting a rare guidance upgrade.
Despite a post-earnings slump and near 52-week lows, Abbott Laboratories' resilient medical device unit, strategic expansion in diabetes care, and a landmark acquisition in cancer diagnostics paint a promising long-term picture for this Dividend Aristocrat.
Barclays initiates coverage of 4D Molecular Therapeutics with an Overweight rating and a $33 price target, citing a favorable industry backdrop with potential M&A tailwinds and shifting focus away from drug pricing pressures. The gene therapy developer also outlined key clinical milestones expected through 2026.
The biotech company Grail has formally submitted its Galleri test for FDA premarket approval, a critical step that could unlock widespread insurance reimbursement and integrate the multi-cancer screening tool into mainstream preventive care.
Pzena Investment Management's latest quarterly commentary reveals its Focused Value Strategy lagged behind the broader value index in Q4 2025, with agricultural sciences firm FMC Corporation highlighted as a key underperformer amid a market dominated by AI and mega-cap stocks.
After a protracted political standoff, France's long-delayed 2026 budget is set for adoption, granting Prime Minister Sebastien Lecornu a hard-won victory but leaving President Macron's domestic reform agenda in limbo ahead of the 2027 election.
The medtech giant inaugurates a Centre of Excellence in Swords, aiming to accelerate development of its Atellica diagnostic systems and bolster Ireland's life sciences sector amid strategic corporate shifts.
